News
Markets are assessing the reshaped US trade landscape after Trump on Thursday laid out steep new tariffs for dozens of ...
The Trump administration is contemplating a pilot program to cover weight-loss drugs under Medicare and Medicaid. The ...
The Trump administration is considering a five-year pilot program to cover weight-loss drugs under Medicare and Medicaid, the ...
Medicare and Medicaid could expand coverage of GLP-1 drugs, such as Ozempic and Wegovy, and pay for patients’ use of the ...
Brazilian pharmaceutical company EMS on Friday said that local pharmacies will start selling its injector pens aimed at treating diabetes and obesity from August 4.
Shares in European pharmaceutical firms slumped following a threat by President Donald Trump to punish them if they don't ...
The Trump administration is exploring a five-year pilot program to include weight-loss drugs like Wegovy, Ozempic, Zepbound, ...
Weight loss medications like Wegovy can be life-changing for people living with obesity or excess weight with related health ...
A doctor has issued a warning to people who use weight loss jabs over the 'golden dose'. The use of GLP-1 medication, such as ...
For a while, Danish drugmaker Novo Nordisk A/S looked unstoppable. It was at the forefront of the weight-loss injection boom as people discovered that its Ozempic shot, originally developed to treat ...
Eli Lilly (LLY) stock and Novo Nordisk (NVO) stock gain as Trump administration to trial Medicare, Medicaid coverage for ...
Global pharmaceutical stocks dropped after President Trump wrote to 17 companies asking them to [cut the costs of drugs]( ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results